Our Research Program

Our Research Program

In our center we study adult, embryonic, and cancer stem cells. The summaries below explain the work done by the core labs of the STaR Center. 

Margaret Goodell, Ph.D. is a leading researcher in stem cell biology and hematology. Her research focuses on the molecular regulation of hematopoietic stem cells, the cells that initiate the formation of different kinds of blood and immune cells. A major goal of her research is to identify genes that are responsible for keeping hematopoietic stem cells in a dormant state as well as those that initiate cell division, which may have implications for understanding the basis of some anemia, and also for cancers of the blood.

Karl-Dimiter Bissig, M.D., Ph.D. has a broad interest in liver disease, ranging from viral hepatitis to metabolic liver disease and liver cancer, and specifically the use of human liver chimeric mice to study these diseases. His lab created the first xenograft model for metabolic liver disease, as well as a novel patient-derived cancer model. These humanized mouse models will help to advance and improve experimental therapies for liver disease.

Malgorzata Borowiak, Ph.D. is an expert in stem cell and regenerative medicine and a McNair Scholar. She works on human pancreatic development and pluripotent stem cell technology using novel molecular approaches to come up with new approaches for regenerative medicine and cellular therapies for type 1 diabetes.

Andre Catic, M.D., Ph.D. joined the Stem Cells and Regenerative Medicine Center and the Huffington Center on Aging at Baylor College of Medicine in 2014 as a CPRIT Scholar in Cancer Research. His laboratory investigates how protein stability impacts gene regulation and cellular metabolism. The goal of this research is to understand, and eventually control, molecular mechanisms that are critical for aging and cancer.

Benjamin Deneen, Ph.D seeks to unlock the enigmatic biology surrounding glial cell development and function in the brain. His work has revealed new paradigms for neural development and brain tumor growth, opening the door for innovative therapeutic interventions. His lab has built an interdisciplinary research program that draws on paradigms from development, disease, physiology, and genomics to better understand the nature of glial cells in the brain.

Katherine King, M.D., Ph.D. began her own laboratory at Baylor College of Medicine after completing her residency, internship and fellowship here. The King Lab uses animal models of infection to investigate the effects of infection and inflammation on hematopoietic stem cell (HSC) biology. Research in the King Lab has implications for prevention and treatment of blood disorders related to inflammatory conditions, responses to infectious diseases, and competition between hematopoietic stem cell clones.

Daisuke Nakada, Ph.D. studies the molecular and cellular mechanisms that regulate self-renewal and differentiation in HSCs and leukemia. The lab uses mouse genetics, genome-editing tools, and epigenome profiling to understand how physiological changes and stress conditions stimulate HSCs, as well as how the mechanisms that regulate HSCs go awry to cause leukemia.

Ron Parchem, Ph.D. focuses on the mechanisms controlling stem cells in development and disease. This work is being applied to gain insight into a broad range of conditions, including common birth defects and brain cancer. For his research on cancer stem cells, Dr. Parchem has recently received funding from the Cancer Prevention and Research Institute of Texas (CPRIT), the V Foundation for Cancer Research and the Andrew McDonough B+ Foundation. He was recently recognized with an award from the Center for Cell and Gene Therapy for excellence in teaching.

Rachel Rau, M.D. has expertise in the biology of hematologic malignancies with a current focus on the genomic and epigenetics of leukemogenesis and chemoresistance. Her lab’s recent work includes a translational study defining the histone modifier, DOT1L as a novel epigenetic target for the treatment of AML with mutations of the gene DNMT3A and a mapping of the mutational landscape of mixed phenotype acute leukemia. 

Noah Freeman Shroyer, Ph.D. is focused on understanding the mechanisms that control intestinal development and homeostasis, and translating this knowledge into novel therapeutic approaches to treat diseases of the intestine such as IBD and colorectal cancer. In addition to mechanistic studies, his lab developed novel organ culture methods to direct differentiation of human pluripotent stem cells into intestinal tissue to study intestinal development and disease, and has used intestinal stem cell-derived organoids in quantitative assays to evaluate intestinal stem cell activity.